Get the Stockscreener App
104.03
3.08%
-3.31
After Hours:
104.03
Zimmer Biomet Holdings Inc stock is traded at $104.03, with a volume of 1.88M.
It is down -3.08% in the last 24 hours and up +5.09% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$107.34
Open:
$106.4
24h Volume:
1.88M
Relative Volume:
1.14
Market Cap:
$20.71B
Revenue:
$7.60B
Net Income/Loss:
$1.08B
P/E Ratio:
19.78
EPS:
5.26
Net Cash Flow:
$1.26B
1W Performance:
-0.69%
1M Performance:
+5.09%
6M Performance:
-1.06%
1Y Performance:
-18.86%
1-Day Range:
$103.44
$106.52
1-Week Range:
$103.44
$111.95
52-Week Range:
$97.69
$133.90
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
104.03 | 20.71B | 7.60B | 1.08B | 1.26B | 5.26 |
|
ABT
Abbott Laboratories
|
130.28 | 225.95B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.42 | 142.29B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.84 | 138.83B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.51 | 117.34B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.51 | 40.28B | 5.72B | 4.17B | 259.90M | 6.97 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Q3 EPS Estimates for Zimmer Biomet Lowered by Zacks Research - Defense World
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario - TradingView
Zimmer Biomet Holdings: Balancing Optimism with Caution Amid Strategic Growth and Market Challenges - TipRanks
Zimmer Biomet Holdings: Strategic Initiatives and Execution Risks Justify Hold Rating - TipRanks
Zimmer Biomet Q1 EPS Forecast Reduced by Zacks Research - Defense World
Paragon 28 clears regulatory hurdle in Zimmer Biomet merger By Investing.com - Investing.com Australia
Paragon 28 clears regulatory hurdle in Zimmer Biomet merger - Investing.com India
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act - Joplin Globe
Tissue Engineering Market Analysis, Competitive Intelligence, and Growth Opportunities to 2030Zimmer Biomet, Stryker Corporation, and 3D BioFibR Lead the Industry - GlobeNewswire
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Lowered by Steward Partners Investment Advisory LLC - Defense World
Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting - PR Newswire
Zimmer Biomet Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Mutual of America Capital Management LLC Decreases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Defense World
Zimmer Biomet SVP Lori Winkler sells $150,649 in stock By Investing.com - Investing.com Canada
Top Executive Cashes In on Zimmer Biomet Holdings Stock - TipRanks
Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference - GuruFocus.com
Zimmer Biomet SVP Lori Winkler sells $150,649 in stock - Investing.com
There May Be Some Bright Spots In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings - Yahoo Finance
FDA clears revision knee implant from Zimmer Biomet - Mass Device
Zimmer Biomet Says Tivanium Knee Implant Component Receives US FDA Clearance - Marketscreener.com
Zimmer Biomet Receives FDA Clearance For Persona® Revision Solution(TM) Femur -March 07, 2025 at 08:03 am EST - Marketscreener.com
Can This New FDA-Cleared Knee Implant Solve the Metal Sensitivity Crisis? - StockTitan
Dental Implant Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, Dentsply Sirona, Institut Straumann, Zimmer Biomet, Kyocera, Henry Schein, Biocon, and Osstem implant - Yahoo Finance UK
Zimmer Biomet Holdings (NYSE:ZBH) Appoints Kristen Cardillo As Chief Communications Officer - Yahoo Finance
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, C - GuruFocus.com
Zimmer Biomet Names Kristen Cardillo As Senior Vice President, Chief Communications Officer - Marketscreener.com
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer - Quantisnow
Zimmer Biomet Holdings, Inc. (ZBH): A Bull Case Theory - MSN
Knee Implants Market to Witness Remarkable Growth with Zimmer, Stryker, Smith & Nephew plc, Johnson & Johnson - openPR
Spine Surgery Robots Market Projected To Witness Substantial Growth 2025-2032:Medtronic, Zimmer Biomet, - EIN News
Zimmer Biomet announces definitive agreement to Acquire Paragon 28 - Today's Medical Developments
Zimmer Biomet Holdings (NYSE:ZBH) Has Announced A Dividend Of $0.24 - Simply Wall St
Zimmer Biomet Holdings (NYSE:ZBH) Has Affirmed Its Dividend Of $0.24 - Yahoo Finance
Is the Market Bullish or Bearish on Zimmer Biomet Holdings? - Benzinga
Prosthetic Disc Nucleus Market Outlook to Exceed US$ 265.8 Million by 2034, Driven by Minimally Invasive Surgery Innovations | Latest Report by Transparency Market Research Inc. - GlobeNewswire Inc.
Pharmaceutical Industry Movers & Shakers - Pharmaceutical Executive
Zimmer Biomet Announces New Schwarzenegger-Led Campaign - Pharmaceutical Executive
Zimmer Biomet's Dollar Dilemma Dampens 2025 Profit Outlook - Finimize
Tekcem bone cement: A breakthrough launch by Zimmer Biomet Holdings - Healthcare Radius
Zimmer Biomet’s $1.75 Billion Notes Offering - Global Legal Chronicle
Weil Advises Underwriters on Zimmer Biomet’s $1.75 Billion Notes Offering - Legal Desire News Network
3 Healthtech Stocks Making Healthcare More Accessible - TradingView
Zimmer Biomet names Jehanzeb Noor as new strategy and innovation chief - Investing.com Canada
Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer – Company AnnouncementFT.com - Financial Times
Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger - The Malaysian Reserve
Zimmer Biomet Launches You’ll Be Back Campaign With Chief Movement Officer Arnold Schwarzenegger - Times-Union Newspaper
Zimmer Biomet sets quarterly dividend at $0.24 per share By Investing.com - Investing.com Australia
Zimmer Biomet Launches You'll Be Back Campaign with Chief Moveme - GuruFocus.com
Zimmer Biomet and Arnold Schwarzenegger promote joint health via new campaign - Yahoo Finance
Ivan Tornos to chair Zimmer Biomet board, company launches new campaign with Arnold Schwarzenegger - Mass Device
Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2025 - The Malaysian Reserve
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.58%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):